| International Session（Symposium）2(JSGE・JGES) |
| Thu. November 21st 14:00 - 16:30 Room 11: Portopia Hotel South Wing Topaz |
| Clinical significance of ustekinumab trough levels and anti-ustekinumab antibodies in patients with Crohn’s disease | |||
| Yasuhiro Morita1, Shigeki Bamba2, Akira Andoh1 | |||
| 1Department of Medicine, Shiga University of Medical Science, 2Division of Clinical Nutrition, Shiga University of Medical Science | |||
|
|||
|
|||
| Backgrounds/aims As for anti-TNF agents, measurement of trough levels and anti-drug antibodies was reported to be important in improving therapeutic outcomes in patients with Crohn’s disease (CD). However, little is known on the trough levels of ustekinumab (UST) and the significance of measurement of anti-ustekinumab antibodies (AUA). Patients and methods Serum UST trough levels and AUA levels were measured using new immunoassays in 30 patients with CD receiving UST maintenance therapy, and were compared with clinical disease activity and blood biochemistry data. Results Serum UST trough levels were 1.93 ± 1.61 μg/ml (n = 30) in CD patients, and 1 of 30 patients (3.33%) were positive for AUAs. The receiver operating characteristic (ROC) curve analyses indicated that an UST trough of 1.35 μg/ml was optimal to maintain negative C-reactive protein (CRP) levels (≤0.3 mg/dl). CRP and erythrocyte sedimentation rate (ESR) levels were significantly elevated in CD patients with UST trough levels <1.35 μg/ml when compared with patients with UST ≥1.35 μg/ml (0.26 mg/dL vs 1.95 mg/dL, P = 0.001, 10.72 mm/h vs 26.36 mm/h, P = 0.005). Conclusions These new assays for serum UST trough and AUA levels are useful for therapeutic drug monitoring and may help guide selection of optimal management strategies for IBD patients. |
|||
|
Index Term 1: Crohn’s disease Index Term 2: Ustekinumab |
|||
| Page Top | |||